FDA is poised to pull Ocali­va as ad­comm doc­u­ments ques­tion post-ap­proval study re­sults

The FDA ap­peared ready to pull its ac­cel­er­at­ed ap­proval of Al­fasig­ma and In­ter­cept Phar­ma­ceu­ti­cals’ rare liv­er dis­ease drug Ocali­va, blunt­ly lay­ing out its ra­tio­nale in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER